CuraGen And TopoTarget Initiate Phase I/II Clinical Trial Of Belinostat (PXD101) Combination Therapy - Details

Link Details 

Submit RSS | Submit Link | Latest Links | Top Hits  
City News Live » Listing Details
ID:1843
Title:CuraGen And TopoTarget Initiate Phase I/II Clinical Trial Of Belinostat (PXD101) Combination Therapy - http://www.medicalnewstoday.com/articles/80885.php
Pagerank:N/A
Description:CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, in combination with the anthracycline idarubicin for the treatment of Acute Myeloid Leukemia (AML). The trial is being conducted at multiple sites in the European Union. [click link for full article]
Category:
Link Owner:
Date Added:August 29, 2007 07:00:00 AM
Number Hits:0